en
Scientific article
English

Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients

Published inHIV medicine, vol. 2, no. 1, p. 35-42
Publication date2001
Abstract

OBJECTIVE: To assess the short-term and long-term effect of a combination of saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed protease inhibitor-naive patients. DESIGN: Prospective open-label multicentre study. PATIENTS AND METHODS: A total of 64 protease inhibitor-naive and stavudine-naive HIV-infected patients with a CD4 count of < 250 cells/microL and > 10 000 HIV-1 RNA copies/mL received saquinavir hard-gelatin capsules, ritonavir and stavudine. Full (drop in viraemia of > 2 log10 and/or < 500 copies/mL) and partial responders (drop to between 500 and 5000 viraemia copies/mL) at week 9 (end of phase I) entered the second phase (additional 12-month period). RESULTS: Fifty-six patients completed phase I, 45 (70%) full responders and nine (14%) partial responders by intent-to-treat analysis. Thirty-nine patients completed phase II, 33 (52%) full responders and two (3%) partial responders. Six patients had < 50 HIV-1 RNA copies/mL at week 9, and 20 (31%) patients at month 12 of phase II. Mean CD4 cell counts increased significantly in the 56 patients from 89 to 184 cells/microL after 9 weeks and from 100 to 292 cells/microL in the 39 patients treated for another 12 months. Higher baseline viraemia and lower baseline CD4 cell counts were not associated with an unfavourable virological response at week 9 and month 12 of phase II. HIV DNA in peripheral blood monocytes decreased substantially (- 1.5 log10) but was detectable in all except one patient at the end of phase II. CONCLUSION: In protease- and stavudine-naive HIV-infected patients with moderate to severe immunosuppression, saquinavir in combination with ritonavir and stavudine caused a substantial long-term decrease in plasma viral load in approximately half the participants and a substantial increase in CD4 cell counts.

Keywords
  • Adolescent
  • Adult
  • Aged
  • Cohort Studies
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • HIV Infections/ drug therapy
  • HIV Protease Inhibitors/administration & dosage/ therapeutic use
  • Humans
  • Immunocompromised Host
  • Male
  • Middle Aged
  • Prospective Studies
  • Reverse Transcriptase Inhibitors/administration & dosage/ therapeutic use
  • Ritonavir/administration & dosage/ therapeutic use
  • Saquinavir/administration & dosage/ therapeutic use
  • Stavudine/administration & dosage/ therapeutic use
  • Switzerland
  • Treatment Outcome
  • Viral Load
Citation (ISO format)
BATTEGAY, M. et al. Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients. In: HIV medicine, 2001, vol. 2, n° 1, p. 35–42. doi: 10.1046/j.1468-1293.2001.00047.x
Main files (1)
Article
accessLevelRestricted
Identifiers
ISSN of the journal1464-2662
521views
0downloads

Technical informations

Creation06/21/2010 10:23:13 AM
First validation06/21/2010 10:23:13 AM
Update time03/14/2023 3:42:44 PM
Status update03/14/2023 3:42:44 PM
Last indexation02/12/2024 6:27:01 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack